TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Emory scientist wins $1.5M NSF grant Emory University chemist Huw Davies got $1.5 million from the National Science Foundation to establish an NSF Center for Chemical Innovation, the Atlanta school said Tuesday. feeds.bizjournals.com |
Setback for Taxus Liberte Stent Heart stents made by market leader Boston Scientific took a scientific drubbing at a big cardiology conference, after rival products from Medtronic and Abbott Laboratories appeared safer in several studies. online.wsj.com |
Earnings Preview: Amgen Amgen (AMGN) is expected to report Q3 earnings Wednesday, October 21 after market open, with a conference call scheduled for 5pm ET. GuidanceAnalysts are looking for EPS of $1.27 on revenue of $3.79B. The consensus range is $1.20-$1.34 for EPS, and $3.73B-$3.88B for revenue, according to First Call. In July, the company reported Q2 EPS of $1.12, beating analysts' expectations of $1.02, and revenue of $5.29B, which was slightly lower than consensus estimates of $5.28B. Positive driver's for Amgen's Q3 results could come from international sales and price increases across the drug company's core product portfolio. Mitigating any benefits from price leverage, Amgen is challenged in its anemia franchise with lower revenue expected from Aranesp. The densumab, Proliia project has been delayed as the FDA has requested a "Complete Response Letter" for the biologics license applications for Prolia in the treatment and prevention of postmenopausal osteoporosis. Complete Story » seekingalpha.com |
BioMed News Bytes: AstraZeneca, Delcath, Unilife Mike Havrilla submits:On 11/19/09, AstraZeneca (NYSE: AZN) announced the submission of a New Drug Application (NDA) to the FDA for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA. This submission is based on the results of a comprehensive program, including data from PLATO (A Study of Platelet Inhibition and Patient Outcomes), the Phase 3 head-to-head trial comparing ticagrelor plus aspirin with clopidogrel (Plavix) plus aspirin. Ticagrelor is the first reversibly binding oral P2Y12 adenosine diphosphate (ADP) receptor antagonist. The mode of action involves inhibiting the action of platelets in the blood to prevent platelets from sticking together, thereby reducing recurrent thrombotic (blood clot) events. On 5/11/09, AZN announced top line results from the phase III trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that BRILINTA (ticagrelor), the investigational oral antiplatelet treatment for acute coronary syndromes (ACS), has achieved a statistically significant primary efficacy endpoint versus Plavix (clopidogrel), in the prevention of cardiovascular (CV) events in patients with ACS. The primary efficacy measure was time to first occurrence of any event from the composite of myocardial infarction, stroke, and CV death. In PLATO, the overall safety profile for BRILINTA was in line with the safety data observed in the Phase 2 studies.Complete Story » seekingalpha.com |
Latest Front in War on Arthritis Scientists looking for ways to repair damaged cartilage—a leading cause of osteoarthritis—are employing horses to test a new method of tissue regeneration that uses concentrated stem cells. online.wsj.com |